Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-03-13 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고 정정신고' (Amendment to the Report on Granting Stock Options). It details changes to previously reported stock option grants, including adjustments to the number of shares and exercise prices due to employee departures and capital changes. This type of filing is a standard regulatory disclosure regarding corporate capital structure and equity compensation, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like DIRS (which is for director/insider trades) or SHA (which is for new share issues).
2024-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of shares, exercise prices, and the list of recipients due to employee departures. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2024-03-13 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고 정정신고' (Amendment to the Report on Stock Option Grant). It details changes to previously reported stock option grants, specifically adjusting the number of recipients and the total number of shares granted due to employee departures. This type of disclosure regarding stock-based compensation and capital structure changes falls under the category of regulatory filings for corporate actions that do not fit into specific financial reporting categories like 10-K or IR, and is best classified as a general regulatory filing.
2024-03-13 Korean
주주총회소집결의 (정기주주총회)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Genome & Company. It outlines the meeting date, location, and specific agenda items such as financial statement approval, articles of incorporation changes, and the election of directors and audit committee members. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2024-03-13 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Genome & Company. It contains the meeting agenda, voting procedures, electronic voting details, and management information (board activities, remuneration, and business outlook). This document is a standard proxy statement/notice of meeting sent to shareholders to inform them of the upcoming AGM and solicit their participation/votes. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category.
2024-03-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). This document details changes in share ownership, including major shareholding notifications and changes in collateralized shares. It is a formal disclosure of significant ownership stakes, which corresponds to the 'Major Shareholding Notification' category.
2024-02-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.